| Bioactivity | SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research[1]. |
| Invitro | SHR-1701 (10 μg/mL)可以抑制 TGF-β 信号通路，激活 PI3K/Akt/Erk 信号通路，挽救淋巴细胞恢复受损的肺癌患者外周血CD8+ T 细胞的抗肿瘤功能[1]。 |
| Name | SHR-1701 |
| CAS | 2891860-17-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bo Cheng, et al. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond). 2022 Jan;42(1):17-36. |